-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Definium Therapeutics, Raises Price Target to $60

Benzinga·07/08/2026 13:30:03
Listen to the news
Stifel analyst Paul Matteis maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $30 to $60.